PAVmed Inc.
PAVM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.01 | -0.01 | 0.37 |
| FCF Yield | -553.75% | -175.47% | -169.62% | -22.06% |
| EV / EBITDA | 1.24 | -0.78 | -0.40 | -2.03 |
| Quality | ||||
| ROIC | -179.19% | -278.44% | -191.14% | -68.49% |
| Gross Margin | -101.60% | -161.83% | -858.62% | -17.00% |
| Cash Conversion Ratio | -1.18 | 0.66 | 0.69 | 0.72 |
| Growth | ||||
| Revenue 3-Year CAGR | 99.53% | 69.90% | – | – |
| Free Cash Flow Growth | 35.71% | 27.92% | -72.43% | -91.45% |
| Safety | ||||
| Net Debt / EBITDA | 1.03 | -0.38 | 0.03 | 1.38 |
| Interest Coverage | -988.60 | -116.80 | -70.98 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 22.70 | 11.91 | 13.85 | 1.11 |
| Cash Conversion Cycle | -21.44 | -61.82 | -230.27 | -1,584.16 |